Research Article
Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects
Figure 3
Average time-curve plots of Emax for drug liking (a) VAS versus Cmax, (b) Emax for drug-liking VAS versus Tmax, and (c) Emax for drug-liking VAS versus AQ (PD population, ). AQ = abuse quotient, Cmax = maximum observed plasma concentration, Emax = mean maximum effect for drug liking, Tmax = time to Cmax, VAS = visual analog scale.
(a) |
(b) |
(c) |